News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

Bleeding Disorders

18 May 2010 CSL Behring Announces Locations and Host Partners for its 9th Annual Gettin’ in the GameSM Junior National Championship

CSL Behring announced today the schedule for its 9th annual Gettin’ in the GameSM Junior National Championship (JNC) competition in golf and baseball. The JNC is a series of one-day athletic events for children with bleeding disorders, such as hemophilia or von Willebrand disease (VWD), and their families. During the JNC young people with a bleeding disorder have the opportunity to connect with and compete against others who have these conditions. The competitions also encourage kids with bleeding disorders to be committed to physical activity that helps keep their muscles healthy and joints strong.

> Read More
13 May 2010 Young Women Urged to Recognize Symptoms of Widely Undiagnosed Bleeding Disorder

To promote the importance of screening young women for von Willebrand disease (VWD), the American Academy of Nurse Practitioners (AANP) today announced the launch of its VWD Young Women’s Education Campaign. Sponsored by CSL Behring, this educational initiative is designed to inform teenage girls and their healthcare providers about the five signs and symptoms of VWD, the most common hereditary bleeding disorder.

> Read More
16 April 2010 CSL Behring Marks World Hemophilia Day with Factor IX Donation to World Federation of Hemophilia

Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units (IU) of factor IX medication made by CSL Behring to the World Federation of Hemophilia (WFH). The donation, channeled through WFH’s United Kingdom chapter, marks World Hemophilia Day 2010 and will support WFH’s progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program.

> Read More
04 February 2010 Global SWIFT Studies Will Evaluate Safety and Efficacy of CSL Behring’s Biostate® for von Willebrand Disease and Hemophilia A

CSL Behring announced today the start of the global clinical trial program SWIFT (Studies with von Willebrand factor [VWF]/Factor VIII) to evaluate the pharmacokinetics, efficacy and safety of Biostate®, a low-volume, highly active, plasma-derived VWF/FVIII concentrate for the treatment of von Willebrand disease (VWD) and hemophilia A. The methodology behind the multi-center trials was detailed in a presentation at the 3rd Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) today.

> Read More
09 November 2009 Patient and Healthcare Provider Convenience Focus of Packaging Enhancements for Humate-P from CSL Behring

CSL Behring has begun packaging Humate-P® (Antihemophilic Factor/von Willebrand Factor Complex [Human]) in a more user-friendly package based on customer market research. These packaging enhancements strive to improve the convenience of treatment for people with von Willebrand disease (VWD), the most common hereditary bleeding disorder in the United States. According to the Centers for Disease Control and Prevention, VWD affects approximately 1 to 2 percent of the U.S. population.

> Read More
Page 17 of 21 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+